drugset / Trial / NCT00763360

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

NCT00763360

Phase 4 Completed 184 enrolled Alcon Research
RandomizedParallel-groupSingle-blind

Summary

The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space, in routine cataract surgery.

Timeline

Start
2008-05
Primary completion
2010-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amvisc Plus Unknown Other
Comparator Sodium Hyaluronate Other / unclassified Other

Indications